Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study (PHTS) group

Matthew J. Bock, Elfriede Pahl, Paolo Rusconi, Gerard J. Boyle, John J. Parent, Clare J. Twist, James K. Kirklin, Elizabeth Pruitt, Daniel Bernstein

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We aimed to determine whether malignancy after pediatric HTx for ACM affects overall post-HTx survival. Patients <18y listed for HTx for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM. A 2:1 matched DCM cohort was also compared. Wait-list and post-HTx survival, along with freedom from common HTx complications, were compared. Eighty subjects were listed due to ACM, whereas 1985 were listed for DCM. Although wait-list survival was higher in the ACM group, post-HTx survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN. Long-term graft survival after pediatric HTx for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HTx are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.

Original languageEnglish (US)
Article numbere12923
JournalPediatric Transplantation
Volume21
Issue number5
DOIs
StatePublished - Aug 1 2017

Fingerprint

Anthracyclines
Heart Transplantation
Cardiomyopathies
Pediatrics
Transplants
Recurrence
Mortality
Survival
Neoplasms
Infection
Graft Survival
Cause of Death
Cohort Studies
Databases
Drug Therapy

Keywords

  • anthracycline cardiomyopathy
  • cancer recurrence
  • chemotherapy-induced cardiomyopathy
  • database review
  • pediatric heart transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy : A report from the Pediatric Heart Transplant Study (PHTS) group. / Bock, Matthew J.; Pahl, Elfriede; Rusconi, Paolo; Boyle, Gerard J.; Parent, John J.; Twist, Clare J.; Kirklin, James K.; Pruitt, Elizabeth; Bernstein, Daniel.

In: Pediatric Transplantation, Vol. 21, No. 5, e12923, 01.08.2017.

Research output: Contribution to journalArticle

Bock, Matthew J. ; Pahl, Elfriede ; Rusconi, Paolo ; Boyle, Gerard J. ; Parent, John J. ; Twist, Clare J. ; Kirklin, James K. ; Pruitt, Elizabeth ; Bernstein, Daniel. / Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy : A report from the Pediatric Heart Transplant Study (PHTS) group. In: Pediatric Transplantation. 2017 ; Vol. 21, No. 5.
@article{7f78fcc8b61f452bbf2b2dfb4a7e469e,
title = "Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study (PHTS) group",
abstract = "We aimed to determine whether malignancy after pediatric HTx for ACM affects overall post-HTx survival. Patients <18y listed for HTx for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM. A 2:1 matched DCM cohort was also compared. Wait-list and post-HTx survival, along with freedom from common HTx complications, were compared. Eighty subjects were listed due to ACM, whereas 1985 were listed for DCM. Although wait-list survival was higher in the ACM group, post-HTx survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN. Long-term graft survival after pediatric HTx for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HTx are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.",
keywords = "anthracycline cardiomyopathy, cancer recurrence, chemotherapy-induced cardiomyopathy, database review, pediatric heart transplantation",
author = "Bock, {Matthew J.} and Elfriede Pahl and Paolo Rusconi and Boyle, {Gerard J.} and Parent, {John J.} and Twist, {Clare J.} and Kirklin, {James K.} and Elizabeth Pruitt and Daniel Bernstein",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/petr.12923",
language = "English (US)",
volume = "21",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy

T2 - A report from the Pediatric Heart Transplant Study (PHTS) group

AU - Bock, Matthew J.

AU - Pahl, Elfriede

AU - Rusconi, Paolo

AU - Boyle, Gerard J.

AU - Parent, John J.

AU - Twist, Clare J.

AU - Kirklin, James K.

AU - Pruitt, Elizabeth

AU - Bernstein, Daniel

PY - 2017/8/1

Y1 - 2017/8/1

N2 - We aimed to determine whether malignancy after pediatric HTx for ACM affects overall post-HTx survival. Patients <18y listed for HTx for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM. A 2:1 matched DCM cohort was also compared. Wait-list and post-HTx survival, along with freedom from common HTx complications, were compared. Eighty subjects were listed due to ACM, whereas 1985 were listed for DCM. Although wait-list survival was higher in the ACM group, post-HTx survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN. Long-term graft survival after pediatric HTx for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HTx are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.

AB - We aimed to determine whether malignancy after pediatric HTx for ACM affects overall post-HTx survival. Patients <18y listed for HTx for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM. A 2:1 matched DCM cohort was also compared. Wait-list and post-HTx survival, along with freedom from common HTx complications, were compared. Eighty subjects were listed due to ACM, whereas 1985 were listed for DCM. Although wait-list survival was higher in the ACM group, post-HTx survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN. Long-term graft survival after pediatric HTx for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HTx are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.

KW - anthracycline cardiomyopathy

KW - cancer recurrence

KW - chemotherapy-induced cardiomyopathy

KW - database review

KW - pediatric heart transplantation

UR - http://www.scopus.com/inward/record.url?scp=85017381592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017381592&partnerID=8YFLogxK

U2 - 10.1111/petr.12923

DO - 10.1111/petr.12923

M3 - Article

C2 - 28378408

AN - SCOPUS:85017381592

VL - 21

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 5

M1 - e12923

ER -